Web3 and Beyond: NFTs, Metaverse and AI Ushering a New Era in Pharmaceutical Innovations

NFTs have exploded into public consciousness, becoming more than just digital artwork or social media avatars like Bored Ape Yacht Club and Cryptopunks. The increasing merger of the physical and digital realms — or “phygital” — coupled with AI and metaverse, brings forth transformative potential, especially in sectors like pharma.

Contrary to popular belief, NFTs are not mere JPEGs but represent secure digital ownership of assets. Initially designed to ensure digital property ownership, NFTs have evolved, even encapsulating real-world assets. An example is the NFT artwork auctioned for $69 million at Christie’s. But beyond their speculative nature, NFTs can disrupt industries with intricate supply chains, like pharmaceuticals. This is evident in the adoption of blockchain in the U.S. FDA’s Drug Supply Chain Security Act (DSCSA).

Blockchain’s Emergence in Pharma

Blockchain offers the pharma industry a transparent, tamper-proof way to document supply chains. Given the magnitude and complexity of pharmaceutical logistics, encrypted, timestamped records offer revolutionary advancements. Singapore’s Zuellig Pharma utilizes blockchain to ensure drug safety, while IBM’s Supply Chain Intelligence Suite equips companies to craft their blockchain networks.

However, NFTs can stretch even further, potentially revolutionizing patient-centric healthcare solutions. With over 1.2 billion clinical documents annually in the U.S., the majority remain scattered or inaccessible. NFTs can resolve this, ensuring security, authenticity, and patient control. Companies like Aimedis are spearheading this, offering patients tokenized medical records ensuring verified, secure data transfers.

But, as we envision the pharma industry’s phygital future, the concept of Web3 becomes pivotal.

Web3’s Potential in Pharma

Web3 proposes a decentralized, open internet, emphasizing user-generated value and sidestepping data breaches and corporate monopolies. Applying these principles to pharma presents intriguing possibilities.

Platforms like Molecule are initiating decentralized drug discovery, where researchers and investors converge without bureaucratic hindrances. Molecule’s groundbreaking approach lets IPs be minted as NFTs, distributing ownership amongst stakeholders. This empowers researchers and participants, ensuring collective ownership of innovations.

Yet, for such open collaboration to prevail, companies must lead from within. RoosterBio, for instance, leverages crypto technologies for its Club RegenMed initiative, offering NFTs as membership tokens to foster a robust community around regenerative medicine.

Recently CVS, the largest pharmacy in the United States, filed a trademark application for virtual goods, non-fungible tokens (NFTs) and collectibles in sectors it typically sells. These include health, wellness, beauty, personal care and prescription drugs, amongst others. CVS is exploring opportunities to create a ‘metaverse health clinic’ — an idea that could revolutionize telehealth and healthcare delivery.

Walmart’s registration of trademarks in similar categories points to a rapidly changing landscape where traditional retailers are rushing to stake their claims in the digital frontier. It suggests that competition in the metaverse will mirror that in the physical world, with companies scrambling to offer unique digital goods and services to consumers. Walmart, with its existing reach and logistics network, could have an advantage in delivering real-world goods linked to digital transactions, much like how its online-to-offline (O2O) model works today.

The Dawning of a Phygital Era in Pharmaceuticals

NFTs, AI, and the metaverse usher a transformative era for pharma. As blockchain-based technologies emerge, they offer novel solutions, from marketing and logistics to patient data management and collaborative research. If we earmark 2021 as NFTs’ breakout year, the ensuing years promise their maturation and revolutionary applications in pharma and beyond. The bridge between the digital and physical, the “phygital” realm, beckons a future brimming with potential.

As the phygital revolution surges forward, the pharmaceutical industry finds itself at an unprecedented crossroads. Leveraging the powers of Web3 technologies, NFTs (Non-Fungible Tokens), and Artificial Intelligence, the sector is combating challenges related to counterfeiting, traceability, and consumer engagement in groundbreaking ways. By 2025, the IoT in pharmaceutical manufacturing is expected to soar to a whopping $75 billion, fueled by an annual growth rate of 12%.

Bridging Two Worlds: The Role of Phygital NFTs in Pharmaceuticals

In the midst of this techno-economic landscape, Phygital NFTs are serving as game-changers. These tokens are inherently resistant to fraud, thanks to their decentralized nature and immutable properties on the blockchain. For instance, Authena AG is pioneering next-gen NFT-based certificates, elevating authentication and traceability of medicines. By merely scanning the NFT on the packaging, consumers can instantly verify product legitimacy, facilitating an ecosystem where transparency is the default.

Metaverse in Healthcare: Beyond the Realm of Possibilities

As per the latest market insights, the global metaverse in healthcare is projected to reach an astounding $800 billion by 2030, with pharmaceuticals poised to occupy a sizable portion of this market. This digital realm is providing unprecedented opportunities for pharmaceuticals to scale, innovate, and connect in ways previously unimaginable.

The Metaverse is gradually becoming a hub for healthcare management. Portals within platforms like Decentraland can offer virtual healthcare seminars, workshops, and even one-on-one consultation experiences. Imagine virtual hospitals and pharmacies that leverage NFT-based records for each patient, offering an advanced yet personalized healthcare experience.

Pharma giants like Pfizer and Novartis are already investing in metaversal technologies, with YOY investment growth hitting almost 40%. Given the expected CAGR and the disruptive potential of the metaverse, the ROI is predicted to be significantly high, making it an alluring sector for investments.

A comprehensive study by Global Healthcare Analytics shows that the pharmaceutical industry is expected to contribute upwards of $150 billion to the overall metaverse economy by 2030. Notably, this number is backed by a CAGR of approximately 25% over the next decade.

Breakdown by Components

• Virtual Drug Trials: $25 billion
• Virtual Medical Consultation: $40 billion
• Blockchain-Enabled Supply Chain: $50 billion
• AI-Integrated R&D: $35 billion
• Drug Development and Research: $400 billion
• Clinical Trials: $300 billion
• Supply Chain Management: $250 billion
• Data Security and Compliance: $250 billion

Virtual Clinical Trials

Virtual clinical trials are no longer a concept from science fiction. Imagine a pharmaceutical company conducting phase-three trials entirely within the metaverse. Participants from around the world can virtually “walk into” a medical facility, take the medication, and submit their experiences and side-effects directly into a blockchain-verified database.

AI: The Catalyst for Revolutionary Supply Chains

According to reports from Future Pharma Metrics, the global market for blockchain and AI in healthcare is slated to reach a stunning $5.6 trillion by 2030. The pharmaceutical sector alone is expected to represent about $1.2 trillion of this burgeoning market.

Artificial Intelligence is the pulse of this revolution, driving everything from drug discovery to the smart management of phygital supply chains. AI algorithms analyze real-time data, monitor supply chain anomalies, and predict bottlenecks. Combined with the Internet of Things (IoT), this technology offers a robust, scalable, and efficient phygital supply chain, destined to disrupt traditional pharmaceutical logistics.

Imagine AI-powered avatars in the metaverse that analyze patients’ genetic makeups and prescribe hyper-personalized medicines. These medicines, each linked to a Non-Fungible Token (NFT), can ensure the highest level of pharmaceutical integrity and traceability. Personalized medicine could reach new heights with AI models that predict patient responses to specific drugs. These AI models, anchored to the blockchain, can offer unprecedented levels of data integrity and security.

Leading pharmaceutical companies like GlaxoSmithKline and Merck are increasing their investment in blockchain and AI technologies. As per investment analysts at HORIZON CAPITAL, the current ROI on investments in blockchain and AI in pharmaceuticals is around 30%, a figure set to rise substantially in the future.

Blockchain: A Pillar of Phygital Trust

Blockchain technology is ensuring the integrity and trustworthiness of the entire system. Not only does it authenticate transactions, but it also secures the supply chain by offering unbreakable encryption and complete visibility from manufacturer to end-user. This comes as a response to the urgent call to fight against the counterfeiting market that is predicted to hit $2.3 trillion by 2022.

Complete end-to-end visibility of drug manufacturing and delivery is now possible within the metaverse. Real-time data on the transportation conditions, expiry dates, and storage facilities can be accessed at any point, thanks to blockchain technology. CVS’s Aetna health insurance division joining blockchain consortiums indicates the company is keen on leveraging blockchain for better claims and payment processing and health data exchanges.

Market Sizing and Forecast: Riding the Phygital Wave

According to recent studies, the phygital healthcare market is set to rise dramatically. The total market capitalization of phygital technologies in healthcare is predicted to reach $450 billion by 2030. Pharmaceuticals will account for a significant portion, given the ever-increasing integration of IoT, NFTs, and AI. By then, an estimated 85% of pharmaceutical companies will be leveraging Web3 technologies in one form or another.

Ushering in Futuristic Healthcare: Use Cases Unplugged

• Real-Time Drug Traceability: With the help of AI and blockchain, every pill, every bottle, can be tracked in real-time, from the manufacturing unit to the pharmacy shelf.
• Patient-Centric NFT Rewards: These could offer consumers redeemable points for attending virtual healthcare workshops or adhering to medication regimes, further propelling proactive healthcare.
• AI-Powered Personalized Treatment Plans: Imagine AI algorithms developing personalized treatment plans, with medicines verified and recorded through NFTs, eliminating any guesswork or inefficiencies.

Conclusion: A Brave New Phygital World Awaits

NFTs, AI, and the metaverse usher a transformative era for pharma. As blockchain-based technologies emerge, they offer novel solutions, from marketing and logistics to patient data management and collaborative research. If we earmark 2021 as NFTs’ breakout year, the ensuing years promise their maturation and revolutionary applications in pharma and beyond. The bridge between the digital and physical, the “phygital” realm, beckons a future brimming with potential.

HashTags

#AI #Web3 #PhygitalNFT #NFT #Metaverse #DigitalTwin #DecentralizedAutonomousOrganizations #DAO #DrugSupplyChainSecurityAct #ZuelligPharma #GMP #IBM #BoredApeYachtClub #Cryptopunks #Adidas, #Budweiser #Pepsi #nike #LMVH #Molecule #Aimedis #Acoer #RoosterBio #ClubRegenMed #NFTHealthcare #BlockchainInPharma #AIRevolution #MetaverseMedicine #DecentralizedPharma #CryptoInHealth #Web3Pharma #NFTCommunityBuilding #pfizer #novartis #virtualclinic #clinicaltrial #supplychain #drugmanufacturing #pharma #pharmaceutical #medicalconsultation #GlaxoSmithKline #Merck #HorizonCapital #FDA #EMA #CVS #Walmart CVS Health CVS Pharmacy Aetna, a CVS Health Company 沃尔玛 Zuellig Pharma IBM Aimedis Avalon Metaverse Aimedis Molecule AG RoosterBio Inc. RegenMed Circles 辉瑞 Pfizer Medical 强生公司 默克 Merck Life Science 诺华 罗氏公司 AbbVie 阿斯利康 Sanofi 荷商葛蘭素史克藥廠 礼来 拜耳 百时美施贵宝 雅培 Gilead Sciences Authena Decentraland The Sandbox GHX Future Pharma Horizon Capital

LinkedIn (https://www.dhirubhai.net/in/ganeshraju07)

https://linktr.ee/grajuakshaya